Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis
Background & Aims
Alcoholic hepatitis (AH) is characterized by hepatocellular damage, inflammation, and fibrosis. We performed a prospective study to associate hepatic expression of the CXC subfamily of chemokines with histology findings and prognosis of patients with AH.
Methods
Liver biopsy samples from 105 patients with AH and 5 normal liver samples (controls) were evaluated for steatosis, inflammation, fibrosis, and cholestasis. Computer-based morphometric analysis assessed the numbers of infiltrating CD3+ T cells and CD15+ cells (neutrophils); terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling staining was used to quantify apoptosis. Expression of CXC and CC chemokines and selected signaling components were assessed by quantitative reverse-transcription polymerase chain reaction; protein levels of interleukin (IL)-8 and Gro-α also were determined by immunohistochemistry. Serum levels of IL-8 and Gro-α were measured by enzyme-linked immunosorbent assay. The Cox regression model identified variables associated with mortality.
Results
Most patients (75%) had severe AH; their 90-day mortality rate was 21.9%. In AH liver samples, expression of the CXC subfamily members IL-8, Gro-α, CXCL5, CXCL6, CXCL10, and platelet factor 4 was up-regulated and compared with controls. The CC chemokine CCL2, but not CCL5, also was up-regulated. Higher expression levels of IL- 8, CXCL5, Gro-γ, and CXCL6 were associated with worse prognosis. Expression of CXC components correlated with neutrophil infiltration and the severity of portal hypertension. In the multivariate analysis, IL-8 protein levels were an independent predictor of 90-day mortality. IL-8 and Gro-α serum levels did not correlate with prognosis.
Conclusions
Hepatic expression of CXC components correlates with prognosis of patients with AH. Reagents that target CXC chemokines might be developed as therapeutics.
Abbreviations used in this paper: ALD, alcohol-induced liver disease, AH, alcoholic hepatitis, HR, hazard ratio, HVPG, hepatic venous pressure gradient, IL, interleukin, CXCR, chemokine receptor, PF4, platelet factor 4, ENA-78, epithelial-derived neutrophil-activating peptide 78, GCP-2, granulocyte chemotactic protein 2, γIP-10, interferon-γ–induced protein 10, IFN, interferon, MCP-1, monocyte chemoattractant protein 1, STAT-1, signal transducer and activator of transcription factor 1, RANTES, regulated upon activation, normally T-expressed, and presumably secreted
Conflicts of interest The authors disclose no conflicts.
Funding This work is supported by grants from the Ministerio de Ciencia y Tecnología, Dirección General de Investigación (SAF 2005-06245), from the Instituto de Salud Carlos III (FIS 05/050567, FIS PI 060085, and PI 080237), and from the European Community (V2006-CE036644). Dr Dominguez received a grant from the Institut d'Investigacions Biomèdiques August Pi i Sunyer and from the Fundación Banco Bilbao Vizcaya Argentaria. Dr Moreno received a grant from the Institut d'Investigacions Biomèdiques August Pi i Sunyer.
PII: S0016-5085(09)00160-7
doi:10.1053/j.gastro.2009.01.056
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.


